<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059626</url>
  </required_header>
  <id_info>
    <org_study_id>18347</org_study_id>
    <nct_id>NCT05059626</nct_id>
  </id_info>
  <brief_title>Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee</brief_title>
  <acronym>Endo2/SA3</acronym>
  <official_title>Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The John B. Pierce Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To determine the effects of SERM and simvastatin interventions on endothelial&#xD;
      dysfunction in women with endometriosis.&#xD;
&#xD;
      Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin&#xD;
      will decrease systemic inflammation and improve specific measures of cardiovascular function&#xD;
      including endothelium-dependent vasodilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis is an estrogen dependent gynecological disorder associated with considerable&#xD;
      chronic pelvic pain, pain during intercourse and is a major cause of infertility. While&#xD;
      endometriosis is a local inflammatory syndrome, the inflammatory process is systemic and&#xD;
      underlies many of the co-morbidities associated with this devastating disease. Endometriosis&#xD;
      and atherosclerotic cardiovascular disease (CVD) are both inflammation-induced diseases.&#xD;
      Robust epidemiologic data demonstrate a clear association between endometriosis, reproductive&#xD;
      risk factors, inflammation and CVD risk, the leading cause of death in women worldwide.&#xD;
      Estrogen exposure is beneficial for women from a CVD standpoint, but the standard of&#xD;
      treatment for endometriosis includes estrogen suppression. This creates a conundrum for the&#xD;
      long-term management of CVD risk in women with endometriosis. Moreover, there is a&#xD;
      significant gap in prior research into the role of inflammatory signaling, CVD risk and&#xD;
      effective interventions to mitigate cardiovascular comorbidities.&#xD;
&#xD;
      Endometriosis and Endothelial Dysfunction: Circulating LDL and oxidized (ox)LDL are two of&#xD;
      many biomarkers of cardiovascular and inflammatory disease elevated in women with&#xD;
      endometriosis. These circulating factors and inflammatory cytokines stimulate the&#xD;
      ubiquitously expressed scavenger lectin-like oxidized LDL receptor (LOX-1) on the vasculature&#xD;
      resulting in increased oxidant production and reduced nitric oxide (NO) metabolism, resulting&#xD;
      in pronounced endothelial dysfunction, one of the earliest detectable indicators of increased&#xD;
      CVD risk. Interestingly, estrogen directly inhibits LOX-1-dependent endothelial dysfunction.&#xD;
      Our working model is that endometriosis-associated systemic inflammatory mediators increase&#xD;
      LOX-1 receptor activity and result in endothelial dysfunction.&#xD;
&#xD;
      Therapies approved in 2018 for the treatment of endometriosis reduce endogenous estrogen&#xD;
      production (elagolix) or selectively modulate estrogen receptors (SERM, bazedoxifene).&#xD;
      Additionally, in preclinical models, therapies that modulate vascular function (statins) are&#xD;
      also efficacious for reducing endometriosis proliferation. However, to date no studies have&#xD;
      evaluated outcomes specific to systemic inflammation and cardiovascular function with these&#xD;
      emerging endometriosis therapies.&#xD;
&#xD;
      This is a single blind placebo control randomized crossover study. Only women with&#xD;
      endometriosis will complete this study. Women will be between the ages of 18 and 45 years and&#xD;
      previously diagnosed (within the past 5 years) with endometriosis. Once consented and&#xD;
      screened, each subject is block randomized to either 30 days of a treatment (Simvastatin or&#xD;
      30 days of SERM (bazedoxifene + conjugated estrogen; BZE+CE)) and , statin, or placebo. This&#xD;
      will be done in a counterbalanced fashion. Subjects will only complete one of the treatments&#xD;
      and the placebo with a 30 day washout to minimize potential carryover effects. On day 30 of&#xD;
      pretreatment or placebo, each subject participates in a cutaneous microdialysis (MD) and flow&#xD;
      mediated dilation (FMD) experiment. After a 30-day washout, the participant will start either&#xD;
      the treatment or placebo and returns to repeat the study with the other pre-treatments&#xD;
      (SERM/Statin/Placebo)undergo the MD and FMD experiments. These treatments/placebo are blinded&#xD;
      to the investigators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a single blind placebo control randomized crossover study. Only women with endometriosis will complete this study. Once consented and screened, each subject is block randomized to either 30 days of a treatment (Simvastatin or 30 days of SERM (bazedoxifene + conjugated estrogen; BZE+CE)) and placebo. This will be done in a counterbalanced fashion. Subjects will only complete one of the treatments and the placebo with a 30 day washout to minimize potential carryover effects. We will use Research Randomizer software. These treatments/placebo are blinded to the investigators.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>These treatments/placebo are blinded to the investigators. The subjects, physician, and the nurse on staff knows which treatment the subject is taking if there are any questions or safety concerns.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in skin blood flow</measure>
    <time_frame>before intervention and 30 days post-intervention</time_frame>
    <description>cutaneous vascular conductance (units = red cell flux/mean arterial pressure)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in peripheral blood flow</measure>
    <time_frame>before intervention and 30 days post-intervention</time_frame>
    <description>brachial artery flow mediated dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LOX-1 activity</measure>
    <time_frame>before intervention and 30 days post-intervention</time_frame>
    <description>LOX-1 receptor expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reproductive hormones</measure>
    <time_frame>before intervention and 30 days post-intervention</time_frame>
    <description>blood hormone concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation</measure>
    <time_frame>before intervention and 30 days post-intervention</time_frame>
    <description>inflammatory cytokine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microRNA activity</measure>
    <time_frame>before intervention and 30 days post-intervention</time_frame>
    <description>microRNA expression</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 days of Simvastatin (10mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bazedoxifene + conjugated estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 days of bazedoxifene + conjugated estrogen (0.45mg/20mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 days of placebo (microcrystalline cellulose filler capsule; 1 pill/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin 10mg</intervention_name>
    <description>Simvastation acts as a systemic LOX inhibitor.</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bazedoxifene 20/Estrogens,Con 0.45Mg Tb</intervention_name>
    <description>Duavee is a selective estrogen receptor modulator.</description>
    <arm_group_label>bazedoxifene + conjugated estrogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for statin and SERM pretreatments.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior&#xD;
             laparoscopy by subject's own physician &lt;5 years prior, and reported by the subject to&#xD;
             the researchers)&#xD;
&#xD;
          -  Tylenol if the subject has acute pain is allowed&#xD;
&#xD;
          -  Contraceptive use is allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)&#xD;
&#xD;
          -  Diabetes (HbA1C .6.5%)&#xD;
&#xD;
          -  BP&gt;140/90&#xD;
&#xD;
          -  Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin&#xD;
             sensitizing, cardiovascular medications)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Taking illicit and/or recreational drugs&#xD;
&#xD;
          -  Abnormal liver function&#xD;
&#xD;
          -  Rash, skin disease, disorders of pigmentation, known skin allergies&#xD;
&#xD;
          -  Diagnosed or suspected metabolic or cardiovascular disease&#xD;
&#xD;
          -  Persistent unexplained elevations of serum transaminases&#xD;
&#xD;
          -  Known allergy to latex or investigative substances&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lacy M Alexander, PhD</last_name>
    <phone>814-867-1781</phone>
    <email>lma191@psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan K Slimak, RN</last_name>
    <phone>814-863-8556</phone>
    <email>sks31@psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The John B. Pierce Laboratory</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nina Stachenfeld, Ph.D.</last_name>
      <phone>203-562-9901</phone>
      <phone_ext>219</phone_ext>
      <email>nina.stachenfeld@yale.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Lacy Alexander</investigator_full_name>
    <investigator_title>Professor of Kinesiology</investigator_title>
  </responsible_party>
  <keyword>Skin blood flow</keyword>
  <keyword>Estrogen</keyword>
  <keyword>Selective Estrogen Receptor Modulator</keyword>
  <keyword>Intradermal Microdialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bazedoxifene</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

